Frankfurt
11.08.25 | 08:41
0,294 Euro
+16,21 % +0,041
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:17 | New last trading day for paid subscription shares (BTA) of AlzeCure Pharma AB | 49 | GlobeNewswire | At the request of AlzeCure Pharma AB, the last trading day in AlzeCure Pharma AB's paid subscription shares will be changed from 2025-08-14 to 2025-08-13.
Instrument:
Paid subscription... ► Artikel lesen | |
| Di | AlzeCure Pharma: New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference | 244 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 29.07. | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 274 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 24.07. | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option | 246 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 23.07. | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed According to Preliminary Results | 229 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 21.07. | AlzeCure Pharma: AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference | 239 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 21, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 16.07. | FDA grants orphan status for AlzeCure's pain drug candidate | 3 | Pharmaceutical Business Review | ||
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 16.07. | AlzeCure Pharma: AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue | 239 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 15.07. | AlzeCure Pharma: AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA | 269 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.07. | The Extraordinary General Meeting of AlzeCure Pharma AB Approved the Decision on the New Issue of Shares | 290 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - At an extraordinary general meeting in AlzeCure Pharma AB on July 2, 2025, the shareholders decided to approve... ► Artikel lesen | |
| 02.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 209 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 17.06. | AlzeCure Pharma: AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue | 320 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 16.06. | Notice To Extraordinary General Meeting In Alzecure Pharma AB | 295 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB are hereby summoned to an extraordinary general meeting to be held on... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma: AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million | 366 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 12.06. | AlzeCure Pharma: AlzeCure receives positive FDA response regarding Phase II/III studies with ACD440 in a rare disease | 387 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 12, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 04.06. | AlzeCure Pharma to present at Redeye Investor Forum on June 11 | 294 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 4, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 03.06. | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on June 10 | 342 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 3, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 14.05. | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2025 | 393 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 14, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 14 May 2025, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2025 | 400 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - March 2025 | 267 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"The... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 325,40 | +3,40 % | Studie eingestellt: Vertex Pharmaceuticals crasht trotz starker Quartalszahlen! | Die Aktie von Vertex Pharmaceuticals steht am Dienstag vor empfindlichen Verlusten. Starke Quartalszahlen werden von einer eingestellten Studie überschattet. Vertex Pharmaceuticals: Einer der konstantesten... ► Artikel lesen | |
| VIATRIS | 8,570 | +2,81 % | Aktienmarkt: Kurs der Aktie von Viatris im Plus (7,75006 €) | Das Wertpapier von Viatris notiert heute ein wenig fester. Das Papier kostete zuletzt 8,97 US-Dollar. Für der Anteilsschein von Viatris steht gegenwärtig ein Preisanstieg 1,82 Prozent zu Buche. Das... ► Artikel lesen | |
| ALTIMMUNE | 2,955 | -0,14 % | Altimmune Appoints Jerry Durso To Succeed Mitchel Sayare As Chairman | ||
| OPKO HEALTH | 1,093 | +2,23 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| JAGUAR HEALTH | 2,160 | -1,37 % | Jaguar Health, Inc.: Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,438 | +5,58 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 9,722 | -0,41 % | Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration | ||
| KIORA PHARMACEUTICALS | 2,450 | +2,73 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases | Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an... ► Artikel lesen | |
| LIPOCINE | 2,930 | 0,00 % | Lipocine Inc.: Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 | SALT LAKE CITY, Aug. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,380 | -1,74 % | Aclaris Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| PHOTOCURE | 5,010 | +0,70 % | PHOTOCURE: Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review | ||
| EUROBIO SCIENTIFIC | 25,150 | +1,00 % | Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy | Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy Paris, July 1st, 2025 Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME... ► Artikel lesen | |
| MEDICURE | 0,700 | 0,00 % | Medicure, Inc.: Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy | WINNIPEG, MB / ACCESS Newswire / June 17, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 25,710 | -0,02 % | Bayer nach Prognoseerhöhung: Das raten jetzt die Analysten | Der DAX-Konzern Bayer hat vergangene Woche seine Jahresziele nach oben geschraubt, allerdings nur auf währungsbereinigter Basis. Vor allem das Agrargeschäft und die Pharma-Division sorgen für positive... ► Artikel lesen | |
| MERCK KGAA | 108,00 | -0,09 % | UBS stuft MERCK KGAA auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Merck KGaA vor Zahlen für das zweite Quartal von 180 auf 162 Euro gesenkt, die Einstufung angesichts des Kurspotenzials aber... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,294 Euro und damit +16,21 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.